Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility of Causation

From General Health to Occupational Exposure: A Legacy of Rigorous Assessment

The legacy of general health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical exposures influence population health. In the context of mass production, this heritage provides a foundation for examining the transition from broad public health messaging to more specialized occupational risk assessment. Historically, discussions around aspirin trials and cardiovascular outcomes have highlighted the need for rigorous evaluation of causal relationships between exposures and health effects, even when initial findings are nuanced by study limitations such as lower-than-expected event rates. This framework now extends naturally to occupational settings where workers may encounter pharmaceutical agents during manufacturing processes. The shift from general health contexts to occupational exposure concerns requires careful consideration of how biological plausibility is assessed when a therapeutic compound, such as avelumab, becomes a potential workplace hazard. In mass production environments, the focus moves from population-level benefits of a drug to the risks faced by those who handle it repeatedly. The same principles of exposure assessment and outcome evaluation that guided large-scale aspirin research now apply to understanding whether occupational contact with avelumab could plausibly influence cancer risk, specifically Merkel cell carcinoma. This pivot demands attention to exposure routes, duration, and dose without invoking specific disease mechanisms, maintaining a neutral academic stance while acknowledging the inherent uncertainty in translating clinical findings to occupational health contexts.

Bridging to Avelumab: Mechanism and Clinical Context

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The biological plausibility of avelumab-related Merkel cell carcinoma causation must be examined in the context of the disease's etiology and the drug's mechanism of action.

Disease Etiology and Drug Mechanism: Assessing Causal Pathways

Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can include a range of inflammatory conditions, such as sarcoidosis, as reported in a case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). While avelumab is used to treat MCC, the question of causation arises when considering whether the drug could induce or worsen the disease itself. Mechanistic pathways linking avelumab to MCC are not directly established in the evidence, but the drug's role in modulating immune responses is relevant.

Evidence on Avelumab and MCC: Treatment Efficacy vs. Causation

In MCC, immune checkpoint inhibition has significantly improved treatment outcomes, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Nevertheless, approximately 50% of patients do not respond or develop ICI-induced irAEs due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For avelumab-refractory patients, efficient and safe treatment options are lacking, and combined ipilimumab plus nivolumab has been used in such cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The evidence does not provide a direct causal pathway from avelumab to the development of de novo MCC; rather, it describes the drug as a treatment for existing MCC. The biological plausibility of avelumab causing MCC would require a mechanism by which PD-L1 inhibition promotes tumorigenesis or reactivates latent viral infection, but such a mechanism is not supported by the provided evidence.

Risk Context and Patient Considerations

Risk anchors include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved for treating metastatic MCC, and its use is associated with irAEs, but there is no mention of warnings about causing MCC. The drug's prescribing information likely includes warnings about irAEs, but the evidence does not specify warnings related to MCC causation. For affected patients, causation-related considerations are complex. If a patient develops MCC after avelumab exposure, the timeline between exposure and documented harm is critical. The evidence does not provide specific timelines for MCC development post-avelumab, but the drug's use in treating MCC suggests that any new MCC diagnosis in a patient previously treated with avelumab for another condition would require careful evaluation. The evidence does not report cases of avelumab causing MCC; instead, it focuses on its therapeutic efficacy and irAEs. In summary, the evidence supports avelumab's role as a treatment for MCC, not as a cause. The biological plausibility of avelumab-related MCC causation is low based on the provided data, as the drug is designed to treat the disease by enhancing immune responses against tumor cells. The risk of developing MCC from avelumab exposure is not substantiated by the evidence, which instead highlights the drug's benefits and associated irAEs. For patients, the primary risk is lack of response or irAEs, not causation of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

Based on current evidence, avelumab is used to treat Merkel cell carcinoma (MCC) and is not known to cause it. The drug works by enhancing the immune system to attack tumor cells. No direct causal pathway from avelumab to de novo MCC has been established.

What is the biological plausibility of avelumab-related MCC?

The biological plausibility is low. Avelumab is an anti-PD-L1 inhibitor that boosts immune response against cancer. While it can cause immune-related adverse events, there is no evidence that it induces MCC. The disease is primarily linked to Merkel cell polyomavirus or UV damage.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.